Illuminating Multiple Sclerosis: Next-Generation PET Tracers for Molecular Insights.

Area of Science:

• Neuroimaging
• Radiochemistry
• Neurology

Background:

• Multiple sclerosis (MS) is a demyelinating disease with complex clinical profiles.
• Conventional MRI has limitations in characterizing MS pathology.
• Advances in PET tracers allow for more specific detection of pathological features in MS.

Purpose of the Study:

• To review novel PET tracers for molecular imaging of demyelination in MS.
• To discuss the pharmacologic properties, imaging protocols, and developmental progress of these tracers.
• To highlight the potential for personalized diagnosis, monitoring, and therapeutic evaluation in MS.

Main Methods:

• Review of PET tracers targeting voltage-gated potassium channels (e.g., [18F]3F4AP).
• Evaluation of PET tracers with high affinity for myelin (e.g., [11C]PiB, [11C]MeDAS).
• Assessment of preclinical and early clinical data for translational relevance.

Main Results:

• [18F]3F4AP targets exposed potassium channels, indicating myelin loss.
• [11C]PiB and [11C]MeDAS show high affinity for myelin, assessing white matter integrity.
• [11C]MeDAS demonstrates selective binding to intact myelin and correlates with histologic myelin content.

Conclusions:

• PET tracers offer enhanced in vivo characterization of MS beyond conventional MRI.
• These tracers enable direct assessment of demyelination and white matter integrity.
• The reviewed agents show translational relevance for personalized MS management.